<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35910808</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1838-7640</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Theranostics</Title><ISOAbbreviation>Theranostics</ISOAbbreviation></Journal><ArticleTitle>Subpial delivery of adeno-associated virus 9-synapsin-caveolin-1 (<i>AAV9-SynCav1</i>) preserves motor neuron and neuromuscular junction morphology, motor function, delays disease onset, and extends survival in hSOD1<sup>G93A</sup> mice.</ArticleTitle><Pagination><StartPage>5389</StartPage><EndPage>5403</EndPage><MedlinePgn>5389-5403</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.72614</ELocationID><Abstract><AbstractText>Elevating neuroprotective proteins using adeno-associated virus (AAV)-mediated gene delivery shows great promise in combating devastating neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS) is one such disease resulting from loss of upper and lower motor neurons (MNs) with 90-95% of cases sporadic (SALS) in nature. Due to the unknown etiology of SALS, interventions that afford neuronal protection and preservation are urgently needed. Caveolin-1 (Cav-1), a membrane/lipid rafts (MLRs) scaffolding and neuroprotective protein, and MLR-associated signaling components are decreased in degenerating neurons in postmortem human brains. We previously showed that, when crossing our SynCav1 transgenic mouse (TG) with the mutant human superoxide dismutase 1 (hSOD1<sup>G93A</sup>) mouse model of ALS, the double transgenic mouse (SynCav1 TG/hSOD1<sup>G93A</sup>) exhibited better motor function and longer survival. The objective of the current study was to test whether neuron-targeted Cav-1 upregulation in the spinal cord using <i>AAV9-SynCav1</i> could improve motor function and extend longevity in mutant humanized mouse and rat (hSOD1<sup>G93A</sup>) models of familial (F)ALS. <b>Methods:</b> Motor function was assessed by voluntary running wheel (RW) in mice and forelimb grip strength (GS) and motor evoked potentials (MEP) in rats. Immunofluorescence (IF) microscopy for choline acetyltransferase (ChAT) was used to assess MN morphology. Neuromuscular junctions (NMJs) were measured by bungarotoxin-a (Btx-a) and synaptophysin IF. Body weight (BW) was measured weekly, and the survival curve was determined by Kaplan-Meier analysis. <b>Results:</b> Following subpial gene delivery to the lumbar spinal cord, male and female hSOD1G93A mice treated with SynCav1 exhibited delayed disease onset, greater running-wheel performance, preserved spinal alpha-motor neuron morphology and NMJ integrity, and 10% increased longevity, independent of affecting expression of the mutant hSOD1G93A protein. Cervical subpial SynCav1 delivery to hSOD1G93A rats preserved forelimb GS and MEPs in the brachial and gastrocnemius muscles. <b>Conclusion:</b> In summary, subpial delivery of SynCav1 protects and preserves spinal motor neurons, and extends longevity in a familial mouse model of ALS without reducing the toxic monogenic component. Furthermore, subpial SynCav1 delivery preserved neuromuscular function in a rat model of FALS. The latter findings strongly indicate the therapeutic applicability of SynCav1 to treat ALS attributed to monogenic (FALS) and potentially in sporadic cases (i.e., SALS).</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichinomiya</LastName><ForeName>Taiga</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savchenko</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongsheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawada</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaojing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wenxi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonds</LastName><ForeName>Jacqueline A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eun Jung</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyanohara</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Hemal H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Piyush M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tadokoro</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsala</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroregeneration Laboratory, Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Brian P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I21 RX003324</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 GM068524</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Theranostics</MedlineTA><NlmUniqueID>101552395</NlmUniqueID><ISSNLinking>1838-7640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051242">Caveolin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016704">Synapsins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051242" MajorTopicYN="Y">Caveolin 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016704" MajorTopicYN="Y">Synapsins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">caveolin-1</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">hSOD1G93A</Keyword><Keyword MajorTopicYN="N">membrane/lipid raft (MLRs)</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">neuromuscular junction</Keyword></KeywordList><CoiStatement>Competing Interests: D.M.R., H.H.P., P.M.P. and B.P.H. hold equity and are non-paid consultants with Eikonoklastes Therapeutics LLC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>1</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35910808</ArticleId><ArticleId IdType="pmc">PMC9330519</ArticleId><ArticleId IdType="doi">10.7150/thno.72614</ArticleId><ArticleId IdType="pii">thnov12p5389</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O'Connor DM, Boulis NM. Gene therapy for neurodegenerative diseases. Trends Mol Med. 2015;21:504&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26122838</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:162&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 2017;16:490&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS) Biochim Biophys Acta. 2015;1852:679&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25193032</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RA, Levina V. et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet. 2014;23:3579&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Rothstein JD. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat Rev Neurosci. 2016;17:383&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Stoklund Dittlau K, Van Den Bosch L. Axonal transport defects and neurodegeneration: Molecular mechanisms and therapeutic implications. Semin Cell Dev Biol. 2020;99:133&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">31542222</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A, Gurfinkel Y, Polain N, Lamont W, Lyn Rea S. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD. Int J Mol Sci. 2021;22(9):4705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125728</ArticleId><ArticleId IdType="pubmed">33946763</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa J, Zemljic-Harpf AE, Mandyam CD, Niesman IR, Lysenko LV, Kleschevnikov AM. et al. Neuron-targeted caveolin-1 promotes ultrastructural and functional hippocampal synaptic plasticity. Cerebral Cortex. 2018;28(9):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095215</ArticleId><ArticleId IdType="pubmed">28981594</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Leem JS, Podvin S, Hook V, Kleschevnikov N, Savchenko P. et al. Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD. Molecular Therapy - Methods and Clinical Development. 2021;21:434&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8065227</ArticleId><ArticleId IdType="pubmed">33981778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Zhang S, Kenna KP, Moll T, Franklin JP, Allen S. et al. Rare variant burden analysis within enhancers identifies CAV1 as an ALS risk gene. Cell Rep. 2021;34:108730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7856549</ArticleId><ArticleId IdType="pubmed">33535055</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M, Tadokoro T, Navarro MR, Platoshyn O, Kobayashi Y, Marsala S. et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26:118&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8171115</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C. et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79:687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H. et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21:2148&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi MG, Cohen-Tannoudji M, Cappelletto A, Giroux B, Roda M, Astord S. et al. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Mol Ther. 2017;25:2038&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell JE, Lim CKW, Krishnan R, McCallister TX, Saporito-Magrina C, Zeballos MA. et al. Targeted gene silencing in the nervous system with CRISPR-Cas13. Sci Adv. 2022;8:eabk2485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769545</ArticleId><ArticleId IdType="pubmed">35044815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM. et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N Engl J Med. 2020;383:151&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochat C, Bernard-Marissal N, Kallstig E, Pradervand S, Perrin FE, Aebischer P. et al. Astrocyte-targeting RNA interference against mutated superoxide dismutase 1 induces motoneuron plasticity and protects fast-fatigable motor units in a mouse model of amyotrophic lateral sclerosis. Glia. 2022;70:842&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9303637</ArticleId><ArticleId IdType="pubmed">34978340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3:eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W, Guo M, Yi L, Liu Y, Li Z, Ma Y. et al. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2020;27:157&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">31819203</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR. et al. Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. Mol Ther Nucleic Acids. 2018;12:75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B. et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc Natl Acad Sci U S A. 2002;99:1604&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada A, Wang S, Jian M, Leem J, Wackerbarth J, Egawa J. et al. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1(G93A) mice. FASEB J. 2019;33:7545&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529340</ArticleId><ArticleId IdType="pubmed">30894019</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G. et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116:2290&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CKW, Gapinske M, Brooks AK, Woods WS, Powell JE, Zeballos CM. et al. Treatment of a Mouse Model of ALS by In vivo Base Editing. Mol Ther. 2020;28:1177&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt SJP, Valencia AP, Le GK, Shah SB, Lovering RM. Pre- and postsynaptic changes in the neuromuscular junction in dystrophic mice. Front Physiol. 2015;6:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4563167</ArticleId><ArticleId IdType="pubmed">26441672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandyam CD, Schilling JM, Cui W, Egawa J, Niesman IR, Kellerhals SE. et al. Neuron-Targeted Caveolin-1 Improves Molecular Signaling, Plasticity, and Behavior Dependent on the Hippocampus in Adult and Aged Mice. Biol Psychiatry. 2017;81:101&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826329</ArticleId><ArticleId IdType="pubmed">26592463</ArticleId></ArticleIdList></Reference><Reference><Citation>Barneoud P, Lolivier J, Sanger DJ, Scatton B, Moser P. Quantitative motor assessment in FALS mice: a longitudinal study. Neuroreport. 1997;8:2861&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9376520</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez-Moreno R, Del Gaizo Moore V, Yoshikawa M, Hampton TG. et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav. 2013;3:431&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869683</ArticleId><ArticleId IdType="pubmed">24381813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligon LA, LaMonte BH, Wallace KE, Weber N, Kalb RG, Holzbaur EL. Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport. 2005;16:533&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15812301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, Seburn KL. Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve. 2005;32:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350398</ArticleId><ArticleId IdType="pubmed">15880561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayworth CR, Gonzalez-Lima F. Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model. Neuroscience. 2009;164:975&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783710</ArticleId><ArticleId IdType="pubmed">19699279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J, Putman CT, Gordon T. Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2007;28:154&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17766128</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J, Comley LH, Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:863&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt SJP, Iyer SR, Shah SB, Lovering RM. Imaging Analysis of the Neuromuscular Junction in Dystrophic Muscle. Methods Mol Biol. 2018;1687:57&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">29067656</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton-Jaimes MF, Kahn J, Israelson A. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS. Proc Natl Acad Sci U S A. 2019;116:14755&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642395</ArticleId><ArticleId IdType="pubmed">31262807</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem. 2002;277:41295&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12189159</ArticleId></ArticleIdList></Reference><Reference><Citation>del Pozo MA, Balasubramanian N, Alderson NB, Kiosses WB, Grande-Garcia A, Anderson RG. et al. Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat Cell Biol. 2005;7:901&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351395</ArticleId><ArticleId IdType="pubmed">16113676</ArticleId></ArticleIdList></Reference><Reference><Citation>Head BP, Patel HH, Tsutsumi YM, Hu Y, Mejia T, Mora RC. et al. Caveolin-1 expression is essential for N-methyl-D-aspartate receptor-mediated Src and extracellular signal-regulated kinase 1/2 activation and protection of primary neurons from ischemic cell death. FASEB J. 2008;22:828&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17905724</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Ichinomiya T, Terada Y, Wang D, Patel HH, Head BP. Synapsin-Promoted Caveolin-1 Overexpression Maintains Mitochondrial Morphology and Function in PSAPP Alzheimer's Disease Mice. Cells. 2021;10:2487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8467690</ArticleId><ArticleId IdType="pubmed">34572135</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, Barbagallo P, Talbot K. The Role of Mitochondrial Dysfunction and ER Stress in TDP-43 and C9ORF72 ALS. Front Cell Neurosci. 2021;15:653688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8047135</ArticleId><ArticleId IdType="pubmed">33867942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XQ, Sawa M, Mobley WC. Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome. Free Radic Biol Med. 2018;114:52&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748266</ArticleId><ArticleId IdType="pubmed">29031834</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearn ML, Schilling JM, Jian M, Egawa J, Wu C, Mandyam CD. et al. Inhibition of RhoA reduces propofol-mediated growth cone collapse, axonal transport impairment, loss of synaptic connectivity, and behavioural deficits. Br J Anaesth. 2018;120:745&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6200100</ArticleId><ArticleId IdType="pubmed">29576115</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli L, Young FL, Boeynaems S, De Decker M, Mehta AR, Swijsen A. et al. C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Sci Adv. 2021;7:3013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034861</ArticleId><ArticleId IdType="pubmed">33837088</ArticleId></ArticleIdList></Reference><Reference><Citation>Campenot RB. Local control of neurite development by nerve growth factor. Proc Natl Acad Sci U S A. 1977;74:4516&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431975</ArticleId><ArticleId IdType="pubmed">270699</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmann J, Goswami RY, Girardo S, Rein N, Hosseinzadeh Z, Hicks MR. et al. A customizable microfluidic platform for medium-throughput modeling of neuromuscular circuits. Biomaterials. 2019;225:119537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294901</ArticleId><ArticleId IdType="pubmed">31614290</ArticleId></ArticleIdList></Reference><Reference><Citation>Santhanam N, Kumanchik L, Guo X, Sommerhage F, Cai Y, Jackson M. et al. Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics. Biomaterials. 2018;166:64&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866791</ArticleId><ArticleId IdType="pubmed">29547745</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoklund Dittlau K, Krasnow EN, Fumagalli L, Vandoorne T, Baatsen P, Kerstens A. et al. Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. Stem Cell Reports. 2021;16:2213&#x2013;2227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8452598</ArticleId><ArticleId IdType="pubmed">33891869</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R. et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun. 2017;8:861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal R, Boeynaems S, Swijsen A, De Decker M, Fumagalli L, Moisse M. et al. HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J. 2021;40:e106177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013789</ArticleId><ArticleId IdType="pubmed">33694180</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14:248&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43:470&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray LM, Talbot K, Gillingwater TH. Review: neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathol Appl Neurobiol. 2010;36:133&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20202121</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang F, Wong H, Ng CM. Rational Clinical Dose Selection of Adeno-Associated Virus-Mediated Gene Therapy Based on Allometric Principles. Clin Pharmacol Ther. 2021;110:803&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33884615</ArticleId></ArticleIdList></Reference><Reference><Citation>Federici T, Taub JS, Baum GR, Gray SJ, Grieger JC, Matthews KA. et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 2012;19:852&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21918551</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C. et al. AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Hum Gene Ther Clin Dev. 2018;29:24&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870071</ArticleId><ArticleId IdType="pubmed">29409358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bey K, Deniaud J, Dubreil L, Joussemet B, Cristini J, Ciron C. et al. Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases? Mol Ther Methods Clin Dev. 2020;17:771&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184633</ArticleId><ArticleId IdType="pubmed">32355866</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer C, Katz N, Dyer C, Goode T, Johansson J, Bell P. et al. Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration. Mol Ther Methods Clin Dev. 2020;17:969&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218226</ArticleId><ArticleId IdType="pubmed">32420410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>